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ABSTRACT - Purpose: Cholesterol is a major lipid constituent of biological membranes which could be 
included in cyclodextrin (CD) cavities. Solubilization and cell extraction of cholesterol have been previously 
performed in order to study its interaction with -CD and methylated -derivatives notably. The present 
work aims at confirming the formation of inclusion complexes between these CDs and cholesterol in order 
to understand their solubilization and cell extraction capacities. Methods: In this context, liquid-state NMR 
spectroscopy (1H NMR studies and ROESY experiments) as well as theoretical studies (molecular 
modeling) have been performed. Results: Rather than preferential conformations, the spectroscopic studies 
showed us the possible interactions between cholesterol and dimethyl--CD, trimethyl--CD, randomly 
methylated -CD or Crysmeb®. Weak interactions were detected using the latter one, confirming the 
advantage of the low substitution to decrease membrane loss of integrity and cytotoxicity. Molecular 
modeling studies should be used to determine which stoichiometry and conformations are energically more 
favorable. The semi-empirical AM1 level was used to investigate both 1:1 and 1:2 complexes whereas 1:1 
complexes were also studied using minimal or double basis sets. Four conformations for each 1:2 
complexes have been envisaged and studied for the methylated CDs. Conclusions: These studies allowed us 





Cyclodextrins (CDs) are water-soluble 
compounds containing a hydrophobic core able to 
solubilize non polar substances. Thus, they have 
been used as excipients to deliver hydrophobic 
drugs (1, 2). Cholesterol is a lipidic molecule, 
member of the sterol family. It is a major lipid 
constituent of biological membranes. 
Due to their affinity for hydrophobic 
molecules, CDs may be able to extract membrane 
cholesterol which could explain the toxicity of 
some methylated derivatives (3, 4). Methylated 
derivatives are assumed to increase drug flux by 
altering barrier properties of the membrane 
through component extraction or fluidization 
(5).Their mechanism of action as absorption 
enhancing compounds (i.e. through the respiratory 
epithelium) may be also explained by their ability 
to transiently open/perturb tight junctions (6, 7). 
In vitro, -CD and its derivatives have a high 
affinity for sterols compared to other lipids and 
because of the relatively high specificity with 
cholesterol, it has been suggested that these 
compounds might be effective in modifying 
cholesterol metabolism in vivo (1). Therefore, 
they could act as potential pharmacological agents 
by influencing the development of the 
atherosclerotic plaque. CDs are currently used to 
modulate membrane cholesterol levels by 
depleting or loading them by the use of 
cholesterol-CD complexes (8). These molecules 
are tools to study specialized membrane 
microdomains called lipid rafts/caveolae because 
of their enrichment in cholesterol particularly (9). 
Specific molecules such as receptors are 
associated with these microdomains explaining 
their involvement in various cellular functions 
(10, 11). By interfering with these microdomains, 
CDs can lead to membrane modifications 
explaining why methyl--CD is currently used to 
study cellular functions (12). Thus, reduction of 
cholesterol level interferes with many processes 
which involve rafts and could be applied for 
treating raft-related infections and diseases (13). 
Moreover, it has been shown that cholesterol 
depletion using methyl--CD increases 
permeability of intestinal cells monolayers by 
displacing specific proteins from cholesterol rich 
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domains associated with tight junctions (14-17). 
In vitro studies using model membranes 
(unilamellar liposomes) have been performed and 
could be used to predict the effects of CDs on 
biological membranes (18-20). Among these, the 
interaction of cholesterol with CDs in aqueous 
solution was investigated quantitatively (phase 
solubility diagrams) and correlated with liposome 
loss of integrity (19, 21). Another method such as 
NMR spectroscopy (22) could be used to 
determine the interaction between CDs and 
cholesterolDifferent authors already studied the 
interactions of cholesterol with -CD and its 
dimethylated (Dimeb) and trimethylated (Trimeb) 
derivatives (23-25). In the present work, 1H NMR 
and ROESY spectra were taken in the same 
conditions in order to compare complexes with 
Dimeb and Trimeb with the one obtained with the 
randomly methylated derivative (Rameb) and a 
low substituted derivative (Crysmeb). Another 
mean to predict interactions are theoretical 
studies. Molecular modeling studies (AM1 
calculations) were used to study different host-
guest inclusion complexes (26-30). Such 
theoretical methods were used here to study 







Dimethyl--cyclodextrin (Dimeb, D.S. 2.0), 
Kleptose Crysmeb (Crysmeb; D.S. 0.5) and 
randomly methylated -cyclodextrin (Rameb; 
D.S. 1.8) were kindly donated by Cyclolab 
(Budapest, Hungary), Roquette Frères (Lestrem, 
France) and Wacker-Chemie GmbH (Munich, 
Germany) respectively. Trimethyl--cyclodextrin 
(Trimeb; D.S. 3.0), a Fluka product, and 
cholesterol were obtained from Sigma-Aldrich 
(Bornem, Belgium). Deuterium oxide (99.97 %) 
was purchased from Eur-isotop (Saint-Aubain, 







 1H NMR studies 
 
One-dimensional 1H NMR spectra were recorded 
at 25 °C on a Bruker Avance 500 operating at a 
proton NMR frequency of 500.13 MHz using a 5 
mm probe and a simple pulse-acquire sequence. 
Acquisition parameters consisted of a spectral 
width of 10,333.6 Hz, a 30° pulse, an acquisition 
time of 3.17 sec and a relaxation delay of 1 s. For 
each sample, 128 scans were recorded. FIDs were 
Fourier transformed with LB = 0.3 Hz and GB = 
0. The resonance due to residual solvent (HOD) 
was used as internal reference. 
CD reference solutions were prepared by 
dissolving appropriate amounts of Dimeb, 
Trimeb, Crysmeb and Rameb directly in 700 µl 
D2O in order to obtain concentrations around 50 
mM (around 46, 51, 41 and 46 mg respectively). 
Sample solutions were prepared by adding excess 
amounts of cholesterol to the CD solutions. The 
resulting suspensions were shaken at 25 °C during 
one hour and then filtered through a 0.4 µm 
membrane filter. The cholesterol reference 
solution (around 11 mM) was prepared in DMSO-
d6. 
Variation of 1H NMR chemical shifts of CD 
protons () caused upon complexation were 
calculated to confirm the interaction with 
cholesterol according to the following formula:  
 
 = (complexed state) - (free state) 
 
Where (complexed state) corresponds to the  chemical 
shifts values in the complexed state and (free state)  




Rotating-frame Overhauser Effect SpectroscopY 
(ROESY) spectra were acquired in the phase 
sensitive mode using the same spectrophotometer 
and Bruker standard parameters (pulse program 
roesyph). Each spectrum consisted of a matrix of 
2K (F2) by 256 (F1) points covering a spectral 
width of 5122.9 Hz. Spectra were obtained from 
the same sample solutions prepared for the 1H 
NMR studies, using a spin-lock mixing time of 
350 µs. Before Fourier transformation, the sine 
apodization function was applied in both 





The geometries were fully optimized without any 
constraint by minimisation of the analytical 
gradient. The nature of the located critical points 
is determined by vibrational frequency calculation 
derived from the second derivative matrix. When 
all the eigenvalues of this Hessian matrix are 






positive, the energy is minimum in each direction 
associated to the variables. Nowadays, Austin 
Model 1 (AM1) calculations (31) can be run 
routinely, the time requested for a geometry 
optimization of around 250 atoms into 200 
iterations being less than 2 hours. This semi-
empirical level is limited to the valence atomic 
orbitals (A.O) only and applies several 
approximations in the calculation of the 
bielectronic integrals. In the case of the complex 
between cholesterol and Crysmeb, the number of 
A.O is 560. The Hartree-Fock ab initio level 
solves the Roothaan equation using a basis set 
which can be minimal or extended (double, 
triple…) without integral approximation and 
using non orthogonal functions. The  value 
accounts for how large the orbital is. With the 
MINI-1 basis set (32), the number of A.O grows 
up to 669 and the time requested is more than 2 
cpu days on a 8 processors machine. The most 
interesting feature of the ab initio level is the 
quality of the calculated geometry very often in 
good agreement with experimental data and also 
the estimation of reliable interaction energies 
(33). The upper step is to use a double basis set 
with additional polarization functions as the 6-
31G(d) basis set (34) and a energy function 
derived from the Density Functional Theory 
(DFT) as B3LYP (35). The basis set used 1229 
functions and the geometry optimization time is 
more than 8 cpu days on a 8 processors machine 
again for cholesterol and Crysmeb. This time 
becomes enormous for cholesterol-Dimeb 
complexes (more than 20 days) to solve the 
equations generated with 1954 functions. 
Figure.1. Schematic representations of the 
conformations envisaged for the 1:1 (AP and AS) and 
1:2 complexes (A, B, C and D). AP: aliphatic chain of 
cholesterol is located towards the primary alcohol 
groups of the CD. AS: aliphatic chain of cholesterol is 
close to the secondary face. Four types of 1:2 
complexes were investigated. A, B, C or D 
conformations depend the relative orientation of the 
CD cavities. 
All the calculations have been performed 
using the Gaussian 03 suite of programs (36). 
Different softwares were used as X-Win 32, 
Molden and Mercury 2.2. to generate illustrations 
of the complexes. 
Two types of 1:1 complexes were studied. 
The AP notation corresponds to the conformation 
where the aliphatic chain of cholesterol is located 
towards the primary alcohol groups of the CD 
while for the AS conformation, the chain is close 
to the secondary face. Four types of 1:2 
complexes (A, B, C or D conformations) were 
investigated depending on the part of cholesterol 
which is included in the CD cavity and on the 
relative orientation of the CD cavities. Schematic 
representations of all the possible conformations 
are presented in Fig.1. 
The atomic coordinates of the -CD molecule 
(refcode POBRON of the Cambridge Structural 
Database) has been selected as starting geometry 
for a complete optimization of the isolated -CD 
(Fig.2). The methylated derivatives were built-up 
by adding methyl groups (CH3) to -CD on each 
glucopyranose units for Dimeb and Trimeb 
(respectively on O-2 and O-6 and O-2, O-3 and 
O-6 positions). Crysmeb which is methylated 
selectively at the secondary O-2 position was 
built-up by adding 4 CH3 on this position for the 
1, 3, 5 and 7 glucose residues leading to a D.S. of 
approximatively 0.57 (close to the one proposed 
by Roquette). Concerning Rameb (D.S. 1.8), 13 
substituents were added on the natural core 
namely 3 CH3 on the O-2 position for the 3, 4 and 
7 glucopyranose units, 3 groups on the O-3 for the 
1, 2 and 5 glucose residues and finally 7 on each 
O-6 position except for the last unit.  
The calculation procedure is the following: 
starting from the optimized geometry of each 
complex, cholesterol and CD were reoptimized 
separately. This procedure allows the 
determination of consistent energetic data, as each 
relative energy is calculated by reference to the 






Atoms notations for cholesterol, according to 
Ravichandran (23), can be seen in Figure 3 which 
shows the 500 MHz 1H NMR spectrum of 
cholesterol in DMSO-d6 up to 6.0 ppm. Due to 
the different media used for the reference and 
sample solutions, no shifts variations were 
calculated upon complexation for cholesterol.    
cyclic part -aliphatic part
cyclic part -aliphatic part cyclic part -aliphatic partA B
cyclic part -aliphatic partC D
cyclic part - aliphatic partAP cyclic part - aliphatic part AS













Figure 3. 1H NMR spectrum of cholesterol in DMSO and atoms notations 



































































































































































































Figure 4. Partial 1H NMR spectra of the cholesterol-CD complex solution (blue) and of the CD solution in D2O with 






















The 1H NMR spectra between 2.7 and 6.1 
ppm of Dimeb in D2O alone (reporting the 
protons) or associated in the complex with 
cholesterol are shown in Fig. 4A. reports the 
differences between 1H NMR chemical shifts 
values of Dimeb protons in the complexed and 
free state (. Proton signals due to 3-H shifted 
upfield prominently followed by the signals due 
to 5-H as it has already been shown (24). Because 
these protons are located inside (Fig. 1) the CD 
cavity, their shifts suggest that cholesterol is 
included inside the Dimeb. The interactions are 
also confirmed in the two-dimensional ROESY 
experiment as correlation spots are clearly 
detectable between cholesterol and the CD inner 
protons (especially 3-H) (5A). 
Also, it is considered that the shifts variations 
of 2-OMe and 6-OMe (Table 1) occur because 
they come into contact with another methyl of a 
second CD confirming the formation of 1:2 
complexes (24). To summarize, as shown in Fig. 
5A, cross peaks connecting the 3-H, 5-H and 6-H 
of Dimeb, as well as 2-OMe and 6-OMe, to the 
18-CH3, 26-CH3, 27-CH3, 21-CH3 and/or 19-CH3 
can be observed. All the results obtained are 
mostly in accordance with those of Nishijo et al. 
(24) and confirm the formation of inclusion 
complexes. To interpret the results in two 
dimensions, mostly the protons corresponding to 
the aliphatic chain of cholesterol have been 
considered. Interpretations concerning the double 
bond and CHOH (cyclic part) would be difficult 
because of the localization of these signals in the 
same area (3.2 to 5.5 ppm) of the spectrum 
corresponding to the ones of the CD and water 
(Fig. 3 and 4A).  
 
 
The protons of Trimeb alone were assigned by 
comparison to the spectrum obtained by Nishijo et 
al. (25) (Fig.4B). As shown in the figure, the 1H 
NMR spectrum of Trimeb in presence of 
cholesterol is deformed when compared to the one 
of Trimeb alone. 
Attributions are thus difficult for Trimeb in 
presence of cholesterol. It was therefore not 
possible to calculate proton shifts variations in 
this case. The broad deformed signals could be 
explained by the superposition of complexed 
species and uncomplexed one because of slow 
exchange rate between complexed species and the 
free one as suggested by the group of Nishijo 
(25). However, cholesterol seems to interact with 
Trimeb as shown on the ROESY spectrum of the 
mixture showing cross peaks between protons of 
cholesterol and methyl groups (3-OMe and 6-
OMe) of the CD (Fig 5B). The formation of 
inclusion complexes between the two molecules 
cannot be excluded. Indeed, correlation spots 
could probably be attributed to an interaction with 
the inner protons which are difficult to assign 
because of broad deformed signals (Fig 5B). 
NMR studies on Rameb are difficult because 
it is not a single pure compound, but rather a 
mixture of randomly methylated molecules of -
CD (38). Only partial proton attributions could be 
done by comparison to the spectrum obtained 
with the well characterized Dimeb. The presence 
of cholesterol is related to an upfield shift of 2-
OMe (+0.02 ppm) which seems to suggest its 
involvement in the interactions while no shift 
appeared for 6-OMe (Fig. 4C). Concerning the 
protons of the inner cavity, 5-H shifted downfield 
in the presence of cholesterol (-0.02 ppm). Data 
on 3-H were inconclusive. So, based on these 
data, only limited conclusions can be made on the 
involvement of the CD protons. On the ROESY 
spectrum (Fig 5C), correlation spots between a 
couple of protons of cholesterol and 2-OMe but 
also 6-OMe can be seen confirming the 
implication of the latter one in the interactions. 
From the two types of NMR experiments, it is 
possible to assume the interactions of cholesterol 
with the methyl groups of Rameb. Despite the 
difficulty to assign the methine protons of the CD 
after complexation, the interactions shown in Fig. 
5C probably involve CD protons such as 3-H or 
5-H. 
In Fig. 4D, protons were assigned for the one-
dimensional spectrum obtained with the Crysmeb 
solution in reference with the work of Bakkour 
(39). As shown in figure 4D and Table 1, no 
significant shifts variations were evaluated for the 
cholesterol-Crysmeb solution. However, weak 
interactions were detected in two dimensions 
between the 18-CH3, 26-CH3, 27-CH3, 21-CH3 
and 19-CH3 of cholesterol and 3-H, 5-H or 6-H of  
the CD (Fig. 5D) confirming the formation of 
cholesterol-Crysmeb inclusion complexes. 
Table 1. Variation of 1H NMR chemical shifts (ppm) 
of Dimeb or Crysmeb protons in the presence of 
cholesterol 
Protons Δδ Dimeb Δδ Crysmeb 
H-1 -0.02 +0.01 
H-2 -0.02 +0.01 
H-3 -0.06 0 
H-4 +0.04 +0.01 
H-5 -0.03 0 
H-6 -0.02 0 
Δδ=δ (Complexed State) -δ (Free State) 





































Figure 5. Two-dimensional ROESY spectrum of a solution containing CD (50 mM) saturated with cholesterol: Dimeb 





























The weakness of the interactions observed could 
be due to the lower solubilization of cholesterol 
with Crysmeb at equivalent concentration of 50 
mM leading to weaker detectable interactions 




As previously determined, phase solubility 
diagrams of cholesterol with Dimeb, Trimeb, 
Rameb and Crysmeb are of the Ap type following 
the Higuchi and Connors classification (21). 
Therefore, in aqueous solutions, two types of 
complexes having molar ratios of 1:1 and 1:2 are 
possible. In the case of cholesterol with Dimeb or 
Trimeb, 1:2 complexes are formed more easily. 
As a matter of fact, K1:2 values calculated by 
Nishijo (24, 25) are higher than K1:1 values (at 
25°C, K1:2-Dimeb = 56,800 M-1 >> K1:1-Dimeb = 109 
M-1; K1:2-Trimeb = 75,500 M-1 >> K1:1-Trimeb = 77 M-
1). Molecular modeling should be used here to 
determine which type of complexes and 
conformations are more favorable. Concerning -
CD, for which no increase in cholesterol aqueous 
solubility could be determined, only the 1:1 
complexes were investigated. 
Results are presented as energetic outcomes 
expressed as interaction, deformation and 
complexation energies (Fig. 6). The interaction 
energy is defined as the difference between the 
energy of the complex and the sum of the energies 
of both partners at their complex geometry. The 
deformation energy is determined by the 
difference between the energy of one of the 
partners of the complex at its equilibrium 
geometry (which is obtained by reoptimization of 
the one found in the complex) and its energy at 
the complex geometry. The complexation energy 
is the difference between the energy of the 
complex and the sum of the energy of each 










Interaction energy: E1 - (E1’ + E1’’) 
Deformation energy: E1’ - E2’ or E1’’ - E2’’ 
Complexation energy: E1 - (E2’ + E2’’) 
 
Figure.6. Schematic representation of the interaction, 
deformation and complexation energies 
 
The results obtained for the 1:1 complexes 
with AM1 calculations are given in Table 2. The 
interaction energies are always favorable although 
they are relatively low compared to other studied 
complexes especially in the case of miconazole 
(26). Complexation energies values are negative 
for the complexes with -CD and Crysmeb which 
means that their formation is energetically 
favorable. On the contrary the high substituted 
methylated CDs show positive values suggesting 
lower probabilities for 1:1 complexes. The 
deformation of cholesterol is weaker than the 
deformation of CDs. This is reasonably due to the 
rigidity of the four-ringed backbone of this 
molecule. Dimeb and Trimeb exhibit more 
deformability upon complexation as suggested by 
the high values obtained compared to the other 
CDs. The highest deformation energies for 
cholesterol are generally obtained with Trimeb 
which means that complex formation should be 
difficult.  
 
Table 2. Interaction, deformation and complexation energies in Kcal/mole for 1:1 complexes with the reference to 
reoptimized CDs and cholesterol (AM1 calculations) 
CD β-CD Dimeb Trimeb Rameb Crysmeb 
Conformation AP AS AP AS AP AS AP AS AP AS 


































Complexation en. -3.254 -4.261 3.058 5.571 0.325 6.418 1.169 0.429 3.440 -1.237 
 







Table 3. Interaction, deformation and complexation energies in Kcal/mole for 1:1 complexes with the reference to 
reoptimized CDs and cholesterol (MINI-1 calculations) 
CD β-CD Dimeb Trimeb Rameb Crysmeb 
Conformation AP AS AP AS AP AS AP AS AP AS 






































For all the five 1:1 complexes, the ab initio MINI-
1 calculations have been performed and the 
results are given in Table 3. What is surprising is 
to obtain non stabilizing interaction energies by 
opposite to the AM1 calculations (Table 2). With 
the MINI-1 basis set, the interatomic distances are 
overestimated and this feature could have a great 
incidence on the interactions occuring in a so 
closed environment. In order to refine the results, 
the geometries of the complexes with each CDs 
except Trimeb have been optimized at the 
B3LYP/6-31G(d) level. The 8 interaction energies 
are generally in good agreement with the AM1 
results (Table 4).  
       This result is satisfactory. Nevertheless, with 
regard to the MINI-1 calculations, the question 
remains open concerning the ability of AM1 to 
describe a very dense H-bond network. Two 
additional rather fast computations (energy only 
without minimization of the gradient) have been 
run using the DFT/6-31G(d) level at the AM1 and 
the MINI-1 geometries noted in Table 4 
B3LYP//AM1 and B3LYP//MINI-1. They 
confirm that AM1 is not very efficient to describe 
H-bond network in inclusion complexes. 
Moreover, the good agreement between 
B3LYP//MINI-1 results and B3LYP//B3LYP 
ones could suggest a significant part of the 
correlation energy in such complexes which is 





Table 4. Comparison of the interaction energies in Kcal/mole for the 1:1 complexes obtained with different calculation 
methods. 
CD β-CD Dimeb Trimeb Rameb Crysmeb 
Conformation AP AS AP AS AP AS AP AS AP AS 
AM1//AM1 -5.182 -5.788 -4.802 -3.536 -5.538 -4.943 -4.921 -4.214 -7.046 -5.074 
MINI-1/MINI-1 4.991 2.437 0.102 6.467 4.111 4.802 5.711 6.024 -0.074 0.197 
B3LYP//B3LYP 0.124 -3.189 -5.607 -1.130 - - -4.871 -2.647 -3.998 -6.167 
B3LYP//AM1 10.529 7.838 11.923 15.450 11.246 17.155 15.529 15.668 10.018 7.904 
B3LYP//MINI-1 -1.856 -4.634 -5.161 -1.589 -2.965 -2.160 -2.187 -3.342 -3.802 -6.097 
 






Figure 7. Structures of the most favorable 1:2 complexes (A: Dimeb; B: Trimeb; C: Rameb and D: Crysmeb) 
 
 
This could explain the differences between MINI-
1//MINI-1 and B3LYP//MINI-1 values. It remains 
that AM1//AM1 seems to give reliable interaction 
energies in rather good accordance with the most 
elaborate results B3LYP//B3LYP else if the poor 
description of the H-bond network effect in the 
complex was counterbalanced by the same poor 
description in the cyclodextrin alone giving rise to 
a cancellation of errors. Nevertheless, for the first 
time, the present study clearly points out the need 
to use more elaborate method than the semi-
empirical ones in order to obtain a good geometry 
description of inclusion complexes with 
cyclodextrins. More in-depth analysis is actually 
under investigation in particular the size of the 
basis set in order to have a reasonable 
compromise between quality and cpu time.  
Because increasing the size of systems 
renders the use of basis sets such as the MINI-1 
prohibitively expensive and time-consuming only 
the semi-empirical AM1 calculations were carried 
out concerning the 1:2 complexes. Results for 1:2 
complexes with Dimeb, Trimeb, Rameb and 
Crysmeb are presented in Table 5. The interaction 
energies calculated in these cases are really higher 
compared to the 1:1 complexes (and values differ 
significantly between the conformations or CD 
envisaged). The lower interaction energies were 
obtained for complexes with Trimeb whereas the 
highest values were obtained with Crysmeb. The 
complexation energies are stabilizing for all the 
conformations envisaged with Dimeb, Rameb and 
Crysmeb. For Trimeb, the C and D conformations 
are not favorable. With each CD, except for 
Crysmeb, higher negative values were obtained 
with the A conformation suggesting higher 
probability for this one. For Crysmeb, the B 
conformation is the most favorable followed by 
the A, D and then C. In Fig. 7, the structures for 
the most favorable 1:2 complexes are represented. 
The complexation energies obtained for the 1:2 
complexes with the methylated derivatives are 
always more favorable than those obtained for the 
1:1 complexes, allowing to confirm the higher 




It is well known that the native -CD exhibits 
poor water solubility which could explain the 
poor solubility of the cholesterol--CD complex 
in water (23). As a consequence, -CD was not 
able to dissolve detectable amounts of cholesterol, 
as shown with the phase-solubility diagram in the 
previous study (21). This CD was thus not used in 
our NMR experiments performed in deuterated 
water. However, the very low concentrations of -
CD used in cellular culture allowed extracting 
relatively high amounts of cholesterol from cell 
membranes (4). Moreover, the production of the 
low-cholesterol butter commercialized in Belgium 
under the tradename "Balade®" implies the use of 
-CD in the manufacturing process to extract 
cholesterol (40, 41). This suggested the possibility 
even for this CD to interact with cholesterol. 
Molecular modeling reinforced this hypothesis as 
complexation energies calculated at the AM1 
level are favorable (Table 2). 
A B
C D






Table 5. Interaction, deformation and complexation energies in Kcal/mole for 1:2 complexes with the reference to 
reoptimized CDs and cholesterol (AM1 calculations). 
Conformation A B C D 
Interaction en. -16.164 -13.458 -16.893 -10.544 
 
Deformation en. 
- Dimeb 1_cyc1. 
- cholesterol 

















     
Complexation en. -7.872 -6.073 -4.939 -6.499 
 
Interaction en. -11.441 -9.632 -6.253 -10.733 
     
Deformation en. 
- Trimeb 1_cyc1. 
- cholesterol 

















     
Complexation en. -9.277 -6.158 7.645 2.253 
     
Interaction en. -17.018 -12.705 -11.473 -10.922 
     
Deformation en. 
- Rameb 1_cyc1. 
- cholesterol 

















     
Complexation en. -11.822 -9.618 -8.279 -5.463 
     
Interaction en. -12.946 -18.706 -12.067 -17.196 
     
Deformation en. 
- Crysmeb 1_cyc1. 
- cholesterol 

















     
Complexation en. -10.217 -13.602 -4.547 -9.814 
 
 
-CD is thus able to interact with cholesterol, 
forming insoluble or very low soluble complexes. 
In the chosen conditions, the present studies, as 
well as phase-solubility diagrams, did not allow 
us to elucidate which type of stoichiometry should 
be the most probable with -CD. 
1H NMR and ROESY experiments enabled to 
investigate the interactions between cholesterol 
and four methylated -CDs substituted in various 
ways. These spectroscopic studies showed us the 
possibility of an inclusion rather than preferential 
conformations. The high substituted Dimeb (D.S. 
2) and Rameb (D.S. 1.8) are efficient cholesterol 
solubilizers or extractors from cell membranes. 
We have previously shown that this could be 
responsible of their destructive effect on 
liposomes and of their cytotoxicity (4, 21). The 
interactions were confirmed by spectroscopic 
studies as shown on the ROESY spectra. In the 
case of Dimeb, it was possible from the 1H NMR 
spectrum to calculate upfield shifts of the inner 
cavity protons which confirm the inclusion. 
Finally, as suggested by molecular modeling at 
the AM1 level, 1:1 complexes with these CDs are 
not favorable while each 1:2 conformations are 
possible. 
In cell culture, Trimeb showed an unexpected 
behaviour as it was not able to extract high 
amounts of cholesterol despite its good 
solubilization properties (4, 21). In membranes, 
cholesterol is associated with other lipids for 
which it can have an affinity and it is not as free 






as in solution. Using cholesterol containing 
liposomes, Trimeb had already shown lower 
destructive effect on the membrane integrity than 
CDs having similar dissolution ability (with D.S. 
around 2) (4). Biological membranes are even 
more complicated than the simplified liposomal 
models and the interactions could be more 
difficult due to the steric bulk of this molecule. 
Deformation energies calculated when using 
Trimeb were generally high which supports this 
suggestion. Moreover, only two of all the 
complexes conformations envisaged with this CD 
gave complexation energies favorable which 
could explain its difficulty to form complexes and 
to extract cholesterol. Another explanation could 
come from the 1H NMR studies. As suggested by 
Nishijo et al. (25), the spectrum obtained upon 
complexation could be due to slow exchange rate 
between complexed species and the free 
molecules. 
The results obtained with the spectroscopic 
studies confirm the lower affinity for the lipidic 
molecule when using the low substituted 
derivative Crysmeb as weaker interactions have 
been observed. This was already evaluated in 
vitro on cell membranes (4) and by phase 
solubility diagrams (21). In this last study, a 50 
mM Crysmeb solution allowed the solubilization 
of very low concentrations of cholesterol (3.5 
mM) compared to the results obtained with the 
other methylated CDs (Dimeb : 11.15 mM, 
Rameb : 12.5 mM, Trimeb : 13.1 mM). As 1H 
NMR spectra are measured in deuterated water, 
similar solubilization capacities as in aqueous 
solutions should be obtained. The lower 
solubilization of cholesterol has been correlated 
with good liposome membrane integrity in 
presence of Crysmeb solutions (21). The better 
cell viability after contact with Crysmeb solutions 
has been attributed to lower cholesterol extraction 
or solubilization (4,7). However, at the AM1 level 
the highest interaction or complexation energies 
were generally obtained with this CD for 1:2 
complexes as well as for 1:1 complexes. 
As a conclusion, these studies allowed us to 
confirm the interactions between cholesterol and 
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